Evidence map›Paper›PMID 35505346›Full record

ArticleBreast cancer research : BCR2022

Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.

Wing-Hong Jonathan Ho, Andrew M K Law, Etienne Masle-Farquhar, Lesley E Castillo, Amanda Mawson, Moira K O'Bryan, Christopher C Goodnow, David Gallego-Ortega, Samantha R Oakes, Christopher J Ormandy

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Many Faces of Oligoadenylate Synthetases.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wing-Hong Jonathan HoGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.
Andrew M K LawGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.
Etienne Masle-FarquharGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.ORCID 0000-0001-9355-8027
Lesley E CastilloGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.
Amanda MawsonGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.
Moira K O'BryanThe School of BioSciences and Bio21 Institute, Faculty of Science, The University of Melbourne, Parkville, Melbourne, VIC, 3010, Australia.ORCID 0000-0001-7298-4940
Christopher C GoodnowGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.ORCID 0000-0001-5296-6155
David Gallego-OrtegaGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.ORCID 0000-0002-2347-7835
Samantha R Oakes *Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia.ORCID 0000-0003-1838-2310
Christopher J Ormandy *Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst Sydney, NSW, 2010, Australia. c.ormandy@garvan.org.au.ORCID 0000-0002-2504-7919
Garvan Institute of Medical Research · AUThe University of Melbourne · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis, we found a mouse with an activating mutation in oligoadenylate synthetase 2 (Oas2), a sensor of viral double stranded RNA, that resulted in an interferon response and prevented lactation in otherwise healthy mice.

methodsTo determine if sole activation of Oas2 could alter the course of mammary cancer, we combined the Oas2 mutation with the MMTV-PyMT oncogene model of breast cancer and examined disease progression and the effects of checkpoint immunotherapy using Kaplan-Meier survival analysis with immunohistochemistry and flow cytometry.

resultsOas2 mutation prevented pregnancy from increasing metastases to lung. Checkpoint immunotherapy with antibodies against programmed death-ligand 1 was more effective when the Oas2 mutation was present.

conclusionsThese data establish OAS2 as a therapeutic target for agents designed to reduce metastases and increase the effectiveness of checkpoint immunotherapy.

Indexed as

2',5'-Oligoadenylate SynthetaseBreast NeoplasmsAdenine NucleotidesAnimalsFemaleHumansInterferonsLigasesMiceOligoribonucleotidesPregnancy2',5'-oligoadenylate2',5'-Oligoadenylate SynthetaseAdenine NucleotidesInterferonsLigasesOligoribonucleotidesBreastCancerImmunotherapyInterferonMammaryOAS2

Identifiers

PMID35505346
PMCPMC9066770
OpenAlexW4225311960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.